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OBJECTIVES: We compared left ventricular regional wall motion, the global left ventricular ejection fraction, and the New York 
Heart Association functional class pre- and postoperatively. 
INTRODUCTION: Endomyocardial fibrosis is characterized by fibrous tissue deposition in the endomyocardium of the apex 
and/or inflow tract of one or both ventricles. Although left ventricular global systolic function is preserved, patients exhibit wall 
motion abnormalities in the apical and inferoapical regions. Fibrous tissue resection in New York Heart Association FC III and IV 
endomyocardial fibrosis patients has been shown to decrease morbidity and mortality. 
METHODS: We prospectively studied 30 patients (20 female, 30±10 years) before and 5±8 months after surgery. The left ventricular 
ejection fraction was determined using the area-length method. Regional left ventricular motion was measured by the centerline 
method. Five left ventricular segments were analyzed pre- and postoperatively. Abnormality was expressed in units of standard 
deviation from the mean motion in a normal reference population.
RESULTS: Left ventricular wall motion in the five regions did not differ between pre- and postoperative measurements. Ad-
ditionally, the left ventricular ejection fraction did not change after surgery (0.45±0.13% x 0.43±0.12% pre- and postoperatively, 
respectively). The New York Heart Association functional class improved to class I in 40% and class II in 43% of patients postop-
eratively (p<0.05). 
CONCLUSIONS: Although endomyocardial fibrosis patients have improved clinical symptoms after surgery, the global left ven-
tricular ejection fraction and regional wall motion in these patients do not change. This finding suggests that other explanations, 
such as improvements in diastolic function, may be operational. 
KEYWORDS: Endomyocardial fibrosis; Wall motion; Restrictive cardiomyopathy; Ejection fraction; Surgery.
INTRODUÇÃO
The clinical and pathological features of endomyocardial 
fibrosis (EMF) were first described by Jack N. P. Davies in 
1948.1 EMF is a restrictive cardiomyopathy characterized 
by fibrous tissue (FT) deposition in the endomyocardium of 
the apex and/or inflow tract of one or both ventricles.2 The 
involvement of the subvalvar apparatus by FT may cause 
atrioventricular regurgitation. Ventricular volumes are usually 
normal or decreased by FT deposition, whereas atrial volumes 
are enlarged and reflect diastolic dysfunction.3 Clinical 
manifestation occurs as right or left cardiac failure, depending 
on the degree of bilateral ventricle involvement.4 Diagnosis 
may be performed noninvasively by echocardiography3 
or magnetic resonance imaging5 via recognition of apical 
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obliteration, atrioventricular valve regurgitation, and 
diastolic dysfunction or, more rarely, by invasive contrast 
ventriculography.6 Although the global LV ejection fraction 
(EF) is preserved in these patients, a previous study by our 
group showed that patients exhibit wall motion abnormalities 
in the apical and inferoapical regions that are unrelated to the 
amount of FT deposition.6 Treatment for patients in the New 
York Heart Association (NYHA) functional classes (FC) III 
and IV who are unresponsive to clinical treatment involves 
surgery.7 The surgical treatment consists of FT resection and 
repair or replacement of atrioventricular valves. This has 
been shown to decrease both morbidity and mortality.8 It has 
been previously reported that surgical treatment improves 
contractile myocardial function,9 although quantitative 
assessment of both global and regional myocardial function 
before and after FT resection has not been performed. 
Therefore, the objective of our study was to quantitatively 
compare LV regional wall motion, the global LVEF, and the 
NYHA FC pre- and postoperatively in EMF patients.
METHODS
We prospectively studied 30 patients (20 female, 30±10 
years) with LV EMF before and 5±8 months after surgery. 
Seventeen patients (57%) had moderate to severe RV 
EMF associated with LV EMF. Thirteen (43%) patients 
were classified in NYHA FC IV and 17 (57%) patients 
in NYHA FC III. The diagnosis of EMF was based on 
clinical presentation as well as electrocardiographic and 
echocardiographic data. The typical echocardiographic 
examination showed apical obliteration, atrial dilation, and 
variable degrees of atrioventricular valve regurgitation.3 
Fourteen (47%) patients underwent LV FT resection, and 16 
(53%) underwent biventricular FT resection. Additionally, 
three patients (10%) underwent mitral valve replacement, 
one (3%) tricuspid replacement, five (17%) mitral valve 
repair, seven (23%) tricuspid valve repair, and 12 (40%) 
mitral and tricuspid repairs. The angiographic images of the 
LV were performed using a pigtail catheter in the anterior 
right oblique projection at 30º, and these images confirmed 
the EMF diagnosis.10 The LVEF was determined by the 
area-length method,11,12 and the regional LV wall motion was 
quantified using the centerline method.13,14 Contrast images 
representing the LV in maximum systole and diastole were 
selected, and their contours were traced onto paper by hand 
for later calculations. The images were analyzed by two 
independent observers who were blinded to identity of the 
patients, as previously described.6 Using a specific program,15 
the ventricular images were recorded in a microcomputer 
with the aid of a digitalizing table (CURTA/model IS/ONE). 
The centerline was constructed in the computer between 
the end-diastolic and end-systolic contours. Motion was 
measured in 100 equidistant chords perpendicular to the 
centerline. The length of each chord indicated the motion of 
the corresponding point in the LV contour. The chords were 
normalized to cardiac size by dividing each length by the final 
diastolic margin, and a unit without dimensions was obtained. 
Abnormality was expressed as units of standard deviation 
from the mean motion of the normal reference population 
comprised of 103 individuals (52 men, 52±10 years) with 
normal LV according to clinical, electrocardiographic, and 
angiographic data. Positive values indicated hyperkinesia, and 
negative values indicated hypokinesia. Chord measurement 
was initiated at the level of the aortic valve, and the chords 
were successively numbered in a clockwise direction from the 
aortic valvular plane to the mitral plane.16 The regions from 1 
to 10 demarcated by the chords were excluded because their 
analysis revealed great variation in length. Chords 81 to 100 
were also excluded since they represented the mitral valve.16 
The LV was divided into five regions: anterobasal (AB, 
chords 10 to 23), anterolateral (AL, chords 24 to 37), apical 
(A, chords 38 to 52), inferoapical (IA, chords 53 to 66), and 
inferobasal (IB, chords 67 to 80) (Figure 1). 
Our Institutional Review Board approved this study, and 
informed consent was obtained from all patients.
Statistical analyses
Paired t-tests were used to compare regional LV wall 
motion and the LV ejection fraction before and after surgery. 
The Mann-Whitney test was used to compare the NHYA 
functional class pre- and postoperatively. A probability (P) 
value less than 0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS v 15 (SPSS 
Inc. Chicago, IL, USA). 
RESULTS
Quantitatively, LV wall motion in the five regions did not 
Figure 1 - The left ventricle was divided into five regions: anterobasal: chords 
10 to 23, anterolateral: chords 24 to 37, apical: chords 38 to 52, inferoapi-
cal: chords 53 to 66, and inferobasal: chords 67 to 80. Chords 1 to 10 were 
excluded due to their high variability in length, and chords 81 to 100 were 
excluded since they represent the mitral valve
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differ between the pre- and postoperative time points (AB: 
pre -0.78 ± 0.25 x post -0.96 ± 0.24, p= 0.559; AL: pre -0.90 
± 0.33 x post -1.26 ± 0.26, p= 0.275 ; A: pre -1.84 ± 0.31 x 
post -1.94± 0.34, p= 0.732; IA: pre -1.69 ± 0.29 x post -2.23 
± 0.39, p= 0.158, IB: pre -0.92 ± 0.21x post -1.24 ± 0.30, p= 
0.347; Figure 2). Similarly, the LVEF did not change after 
surgery (0.45±0.13% x 0.43±0.12 pre- and postoperatively, 
respectively). However, the NYHA FC was classified 
as III in 17 patients (57%) and IV in 13 patients (43%), 
and it improved to I in 40% and II in 43% of the patients 
postoperatively (p<0.05, Figure 3). Seventeen percent of the 
postoperative patients remained in NYHA FC III and IV. 
DISCUSSION
This report demonstrates that LVEF and quantitative 
regional wall motion do not change even though EMF 
patients show improvements in their clinical symptoms after 
surgery. Regional wall motion has been shown to be present 
in EMF patients in A and IA regions,6 and we demonstrate 
herein that the wall motion abnormalities do not change 
after FT resection. In histopathological specimens obtained 
from surgical resection, the FT extends irregularly into the 
underlying myocardium17 and separates groups of myocardial 
fibers. Additionally, FT is composed of a superficial compact 
Figure 3 - The NYHA functional class improved to I in 40% and II in 43% of the patients postoperatively
Figure 2 - Quantitatively, LV wall motion in the five regions did not differ pre- and postoperatively in EMF patients; AB – anterobasal; AL - anterolateral; 
A - apical; IA - inferoapical; IB – inferobasal
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layer of collagen and a deeper layer of loose FT, and the 
myocardial fibers commonly show degenerative changes. 
The apical and inferoapical wall motion abnormalities are 
maintained as the FT is resected, likely by FT that penetrates 
into the myocardium and/or myocytes that have degenerated. 
Our findings are reinforced by the mildly depressed LVEF 
that does not change after resection. In contrast to previous 
studies affirming that surgery improves contractile function 
by releasing the myocardium,9,18 no changes in global or 
regional functions were observed in our study. In contrast to 
previous work, we used a quantitative technique to compare 
regional wall motion in EMF patients before and after 
surgical resection. 
However, the high rates of symptom improvement 
require an explanation. It is likely that FT resection causes 
an increase in LV volumes, which may improve ventricular 
filling, produce a less steep pressure-volume relationship, 
and improve diastolic function. We have previously shown 
that EMF patients exhibit delayed myocardial relaxation, 
increased ventricular stiffness, and enlarged left atrium 
volumes.3 Potential changes in diastolic function after FT 
resection were not assessed, although the present study 
suggests that further evaluation of such changes would be 
valuable. 
In our study, surgery resulted in an impressive response, 
as measured by the NYHA FC. We have previously shown 
that the NYHA FC is strongly related to maximum oxygen 
consumption in EMF patients19,20 and is a major factor in the 
decision for surgical indication.10 Early surgery is the only 
intervention that may reduce morbidity and improve survival 
in patients presenting NYHA FC III and IV.10 Medically 
treated symptomatic patients have a mortality rate of 50% 
over 2 years,21 whereas the operative mortality rate is about 
15% to 20%. Furthermore, the actuarial probability of 
survival at 17 years post-treatment is 55% when operative 
mortality is considered.22 
The improvements in morbidity and mortality observed 
with surgical treatment are only achieved in symptomatic 
patients. Clinical treatment of EMF patients as well as 
patients with other restrictive cardiomyopathies is complex, 
because hypovolemia or hypervolemia can lead to 
hypotension or pulmonary congestion, respectively.23 
Additionally, medical treatments must be used with caution 
because vasodilators may cause hypotension and medications 
that decrease heart rate in an attempt to improve ventricular 
filling have not proved beneficial.23 
EMF is a “neglected” disease in cardiology because it 
almost exclusively affects the poorest people in developed 
countries.24 EMF is still prevalent in tropical areas of South 
America, Africa, and Asia, and over 12 million people 
are currently estimated to have EMF.25 Endomyocardial 
fibrosis is found in 9% of the general population in affected 
regions of Mozambique,9 accounting for 15% to 25% of all 
cardiac deaths in equatorial Africa. Unfortunately, EMF 
most severely affects those regions least equipped for 
cardiovascular surgery.25 
The cause and pathogenesis of EMF remain unknown. 
The unifying explanation considers EMF and Loeffler’s 
syndrome to be extremes of the same disease due to the 
similarity between the heart lesions in both disorders.26 
Several variables, including environmental (geography, 
nutritional deficiency, high cerium intake, and parasitic 
infectious) and host (genetic predisposition, ethnicity, 
hypereosinophilia, autoimmunity, and inflammatory 
processes) factors, are involved in the pathogenesis of 
EMF.25-27 Of note, eosinophils remain a major risk factor 
for EMF in Uganda and Nigeria, but their role in the 
pathogenesis of this disease is still not understood.28
The age and sex predominance of EMF vary depending 
on the region considered. As observed in our study, 
EMF mainly affects young female adults in Brazil. Male 
predominance occurs in Kerala and Nigeria, whereas the 
disease strikes primarily female patients in Uganda.25 The 
incidence in Africa peaks in people between the ages of 11 
and 15 years.9 In Uganda, bimodal peaks occur at age 10 and 
age 30.26 In contrast, heart failure in developed countries is a 
disease of the elderly.29
Ventricular involvement depends on the geographic 
area. In our hospital, 52.4% of the patients had biventricular 
involvement, 27.9% RV involvement, and 30.7% LV 
involvement.30 RV and biventricular involvement are more 
common in Africa.9, 31
CONCLUSION
Even though EMF patients show improvements in 
clinical symptoms after surgery, the LVEF and quantitative 
regional wall motion do not change. These results suggest 
that the improvements in symptoms are due to improvements 
in diastolic function.
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